Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

Palatin Technologies has completed its Phase II study, BMT-801, evaluating the joint administration of melanocortin 4 ...

Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1 RA/gastric inhibitory polypeptide (GIP) medication tirzepatide, have gained widespread ...

Users of weight-loss medications like Ozempic and Tirzepatide are going blind, according to a new study. The study, published in JAMA Opthalmology, reports multiple cases of serious eye complications ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.